Sign In
Buy GTHX
$7.15
+0 (+0%)
At Close: Dec 16, 2024
G1 Therapeutics (GTHX) Reports Q3 Loss, Tops Revenue Estimates
09:12am, Wednesday, 03'rd Nov 2021
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 2.91% and 12.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: G1 Therapeutics Q3 Earnings
08:03am, Wednesday, 03'rd Nov 2021
G1 Therapeutics (NASDAQ:GTHX) reported its Q3 earnings results on Wednesday, November 3, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
Proactive use of trilaciclib prior to chemotherapy in certain patients significantly reduced the use of G-CSFs, ESAs, and RBC transfusions on or after week five of chemotherapy Proactive use of trilac
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 01'st Oct 2021
RESEARCH TRIANGLE PARK, N.C., Oct. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercis
G1 Therapeutics Announces Permanent J-Code from Centers for Medicare and Medicaid Services
07:45am, Friday, 01'st Oct 2021
Effective Today, New J-code to Streamline Reimbursement Effective Today, New J-code to Streamline Reimbursement
G1 Therapeutics Announces New Supplemental COSELA™ (Trilaciclib) Sales Force
06:45am, Wednesday, 15'th Sep 2021
- New G1 Sales Force to Focus on Top Tier Accounts to Accelerate Sales Activities - - New G1 Sales Force to Focus on Top Tier Accounts to Accelerate Sales Activities -
G1 Therapeutics to Participate in Two Upcoming September Conferences
07:45am, Friday, 03'rd Sep 2021
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upc
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 03'rd Sep 2021
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerci
G1 Therapeutics: Poised To Deliver A Blockbuster
10:57am, Saturday, 28'th Aug 2021
G1 Therapeutics is now a commercialization-stage operator having a potential mega-blockbuster (Cosela). Cosela is filling a heightened demand to treat myelosuppression associated with chemotherapy.
G1 Therapeutics: Pullback Presents Opportunity
09:00pm, Sunday, 15'th Aug 2021
GTHX is down considerably from its February highs. Recently approved Cosela is starting out well.
Here's Why G1 THERAPEUTICS (GTHX) is Poised for a Turnaround After Losing 16.4% in 4 Weeks
11:25am, Thursday, 05'th Aug 2021
The heavy selling pressure might have exhausted for G1 THERAPEUTICS (GTHX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ana
G1 Therapeutics, Inc. (GTHX) CEO John Bailey on Q2 2021 Results - Earnings Call Transcript
11:19pm, Wednesday, 04'th Aug 2021
G1 Therapeutics, Inc. (GTHX) CEO John Bailey on Q2 2021 Results - Earnings Call Transcript
G1 THERAPEUTICS (GTHX) Reports Q2 Loss, Tops Revenue Estimates
06:19pm, Wednesday, 04'th Aug 2021
G1 THERAPEUTICS (GTHX) delivered earnings and revenue surprises of 2.08% and 144.77%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics Announces Appointment of Andrew Perry as Chief Commercial Officer
06:50am, Monday, 02'nd Aug 2021
Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., July 19, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the U.S. Food and Drug Administration (F
